Eurobank posts €738m profit in first half of 2026— Cyprus contributes €231m

Eurobank reported €738m net profit for H1 2026, with adjusted net profit of €776m (+9.2% y/y). Cyprus contributed €231m adjusted net profit, down 7.7% y/y. The bank said loan book grew 10% annually and raised its 2026 EPS growth outlook to well above 10%, targeting near-17% return on tangible book value.

Original reporting
Published Jul 31, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Eurobank posts €738m profit in first half of 2026— Cyprus contributes €231m — source image
Decision brief

The 30-second read

Med
01

Why it matters

The key tradable element is the raised full-year outlook, supported by quantified operating income growth, lower provisions, and strong capital ratios, while noting NIM compression and a decline in Cyprus adjusted profit year over year.

02

Market read

Eurobank’s guidance upgrade and strong 1H metrics (profitability, loan growth, capital) are likely to drive near-term repricing of 2026 earnings expectations, with Cyprus as a notable contributor.

03

What to watch

Loan growth is strong, but traders may focus on whether provisions and non-performing exposure (2.5% NPE, 82.4% coverage) can hold up if macro conditions weaken.

Relevance 8/10Novelty 7/10Timing: reported 1H 2026 results and same-day full-year outlook update

Background

The article is a first-half 2026 performance update for Eurobank, emphasizing profitability, credit growth, deposit growth, and capital strength, with a specific focus on Cyprus.

Market effects

Signals resilience in Greek and regional bank credit demand and deposit growth, potentially supporting sentiment across European lenders with similar exposure.

Cyprus contribution (€231m adjusted profit) and loan/deposit growth highlight continued strength in the bank’s non-Greek footprint despite regional uncertainty.

Limited direct global spillover, but reinforces the broader European banking narrative around NIM pressure versus fee income and credit quality stability.

Counterpoint

NIM declined 5 bps to 2.46% and Cyprus adjusted profit fell 7.7%, so the guidance raise may rely on continued growth that could be sensitive to rates and geopolitics.

Key entities

  • Eurobank

    Reported 1H 2026 net profit of €738m, disclosed loan/deposit dynamics, and raised full-year EPS growth guidance.

  • Fokion Karavias

    CEO quoted on performance drivers, geopolitical uncertainty, and confidence in exceeding full-year targets.

  • European Central Bank (ECB)

    Referenced as having lower interest rates contributing to a slight NIM decline.

  • European Commission

    Provided projections for Cyprus GDP growth and inflation cited in the article.

Related articles

Med

Eurobank highlights Cyprus role in regional growth plans

Eurobank reported first-half 2026 net profit attributable to shareholders of €738m, up from €691m a year earlier, and adjusted net profit of €776m. The bank cited Cyprus as a core growth market, supported by merger integration, higher lending and deposits, and insurance deals. It also reported group assets €113bn, loans €58.1bn, deposits €86.4bn, and guidance for ~17% RoTBV in 2026.

$INBKMed

Eurobank & Inbank Launch Embedded Finance in Greece

Eurobank and Estonia-based Inbank plan a 50/50 joint venture to build an embedded finance platform in Greece offering BNPL, point-of-sale financing, and consumer credit. The partners are pursuing Bank of Greece licensing, with commercial operations expected in Q1 2027. Inbank says it has 6,200+ merchant partners and 847,000+ active credit agreements.

$VSXYMedAI 8/10

Should you buy Victoria’s Secret stock after today’s sharp selloff?

Victoria’s Secret (VSXY) shares fell 5.67% premarket after Q3 operating income guidance missed estimates, though full-year outlook improved. Q2 revenue was $1.61B, slightly below consensus, while adjusted EPS beat estimates. Management cited increased marketing investment and one-time tariff refunds as factors. The stock has gained 269.22% over one year but faces technical and margin concerns.

$WLYMed

JOHN WILEY & SONS, INC. (WLY): Results of Operations and Financial Condition

JOHN WILEY & SONS, INC. (WLY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Wiley Reports First Quarter 2027 Results; Q1 in line with expectations and full year outlook reaffirmed Strength in Research and AI offset by prior year comparison and softness in Learning – Emerald integration ahead of schedule September 3, 2026 - Hoboken, NJ – Wiley (NYSE: WLY)

$OCULMedAI 8/10

Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

Ocular Therapeutix (OCUL) reported Q2 2026 results, highlighting AXPAXLI's progress for wet age-related macular degeneration. The FDA confirmed the NDA filing timeline, with potential for a faster review. Costs rose, with R&D at $54.1M, marketing at $17.3M, and net loss widening to $78.8M. Cash reserves decreased to $598.6M. AXPAXLI's data suggests fewer patient injections, and early market research shows high adoption potential. Institutional interest grew, but short interest remains high.